Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Given Average Rating of “Moderate Buy” by Brokerages

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) has earned a consensus rating of “Moderate Buy” from the fifteen research firms that are presently covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating on the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $182.47.

Several research firms have recently weighed in on JAZZ. Robert W. Baird lifted their target price on shares of Jazz Pharmaceuticals from $154.00 to $162.00 and gave the company an “outperform” rating in a report on Monday, November 18th. Piper Sandler reiterated an “overweight” rating and issued a $176.00 price objective (up previously from $163.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday. Cantor Fitzgerald lowered shares of Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and increased their target price for the stock from $140.00 to $150.00 in a research note on Wednesday. HC Wainwright restated a “buy” rating and issued a $200.00 price target on shares of Jazz Pharmaceuticals in a research note on Friday, November 22nd. Finally, Morgan Stanley upgraded Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and increased their price target for the stock from $140.00 to $175.00 in a research report on Thursday, December 12th.

Insider Transactions at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,500 shares of the stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $122.31, for a total value of $183,465.00. Following the completion of the sale, the chief executive officer now owns 439,744 shares in the company, valued at approximately $53,785,088.64. This represents a 0.34 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last three months, insiders have sold 5,053 shares of company stock valued at $617,442. Corporate insiders own 4.20% of the company’s stock.

Institutional Investors Weigh In On Jazz Pharmaceuticals

A number of large investors have recently made changes to their positions in the stock. CWA Asset Management Group LLC acquired a new position in Jazz Pharmaceuticals during the third quarter worth $3,197,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Jazz Pharmaceuticals by 135.3% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 174,078 shares of the specialty pharmaceutical company’s stock worth $19,394,000 after acquiring an additional 100,112 shares during the period. Centre Asset Management LLC acquired a new position in shares of Jazz Pharmaceuticals during the 4th quarter valued at about $9,335,000. Moloney Securities Asset Management LLC acquired a new position in shares of Jazz Pharmaceuticals during the 4th quarter valued at about $464,000. Finally, Pacer Advisors Inc. grew its holdings in shares of Jazz Pharmaceuticals by 15.3% in the third quarter. Pacer Advisors Inc. now owns 2,099,378 shares of the specialty pharmaceutical company’s stock valued at $233,892,000 after purchasing an additional 278,465 shares during the period. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals Stock Up 3.2 %

Shares of JAZZ stock opened at $144.17 on Friday. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46. Jazz Pharmaceuticals has a twelve month low of $99.06 and a twelve month high of $148.06. The stock has a 50 day moving average of $125.42 and a 200 day moving average of $118.44. The stock has a market cap of $8.72 billion, a P/E ratio of 20.31, a P/E/G ratio of 1.04 and a beta of 0.56.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.